Literature DB >> 16731612

Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: time for a change.

F Fitzpatrick, T McGaley, L Rajan, R Crowley, M Turley, H Humphreys, E Smyth.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731612      PMCID: PMC1860391     

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  5 in total

Review 1.  Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Authors:  A L Somerville; D H Wright; J C Rotschafer
Journal:  Pharmacotherapy       Date:  1999-06       Impact factor: 4.705

2.  Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment.

Authors:  John F Wilson; Alan C Davis; Caroline M Tobin
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

3.  New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.

Authors:  P F Smith; W P Petros; M P Soucie; K R Copeland
Journal:  Ther Drug Monit       Date:  1998-04       Impact factor: 3.681

4.  Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.

Authors:  C M Tobin; J M Darville; A H Thomson; G Sweeney; J F Wilson; A P MacGowan; L O White
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

5.  Falsely elevated serum vancomycin concentrations in hemodialysis patients.

Authors:  S L Follin; B A Mueller; M K Scott; M A Carfagna; M A Kraus
Journal:  Am J Kidney Dis       Date:  1996-01       Impact factor: 8.860

  5 in total
  1 in total

1.  Independent specimens are important.

Authors:  P J Twomey; A Viljoen
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.